---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-336670"
form_type: "8-K"
ticker: "AMLX"
cik: "0001658551"
company_name: "Amylyx Pharmaceuticals, Inc."
filed_at: "2026-08-06T11:02:19+00:00"
generated_at: "2026-08-06T11:07:03.905374+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Amylyx Q2 net loss $43.4M; Phase 3 PBH topline data expected late Aug/early Sep 2026

## Summary
- Net loss of $43.4M ($0.39 per share) vs $41.4M ($0.46 per share) in Q2 2025.
- Cash, equivalents, and short-term investments $250.8M at June 30, 2026; runway into 2028.
- R&D expenses $23.8M (down from $27.2M); SG&A $21.9M (up from $15.6M) on legal and commercial investment.
- Last participant completed final visit in Phase 3 LUCIDITY trial of avexitide in PBH; topline data on track for late Aug/early Sep 2026.
- Expanded Access Program for avexitide initiated; second research collaboration with Gubra A/S announced.

## SEC filing metadata
- accession: 0001193125-26-336670
- form_type: 8-K
- ticker: AMLX
- cik: 0001658551
- company_name: Amylyx Pharmaceuticals, Inc.
- filed_at: 2026-08-06T11:02:19+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1658551/000119312526336670/0001193125-26-336670-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1658551/000119312526336670/amlx-20260806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-336670
- JSON: https://secwatch.observer/filing/0001193125-26-336670.json
- Plain text: https://secwatch.observer/filing/0001193125-26-336670.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.